Composition and method for treating nosebleeds

Abstract

A composition and method for treating nosebleed, that is, epistaxis. The composition comprises bismuth subgallate and a vasoconstriction agent, preferably oxymetazoline. The composition is preferably a paste administered intranasally.

1 . A method for treating epistaxis in a human, said method comprising a step of administering to a human patient suffering from epistaxis an effective amount of a composition comprising bismuth subgallate and a vasoconstriction agent together in a ratio of 0.01-5 ml aqueous liquid containing vasoconstriction agent per 1 gram of bismuth subgallate powder, said composition being effective for treating epistaxis in a human when administered to a human patient suffering from epistaxis, said bismuth subgallate being present in said composition in a weight percent effective to assist in slowing or stopping epistaxis, said vasoconstriction agent being present in said composition in a weight percent effective to assist in slowing or stopping epistaxis, said weight percent of bismuth subgallate and said weight percent of said vasoconstriction agent being effective, in combination, to treat epistaxis when said composition is administered to a human patient suffering from epistaxis. 
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1 , wherein said ratio is 0.1-3 ml aqueous liquid containing vasoconstriction agent per 1 gram of bismuth subgallate powder. 
     
     
         4 . The method of  claim 1 , wherein said composition is 0.00001 to 20 ratio is 0.3-2 ml aqueous liquid containing vasoconstriction agent per 1 gram of bismuth subgallate powder. 
     
     
         5 . The method of  claim 1 , wherein said vasoconstriction agent is selected from the group consisting of epinephrine, phenylephrine, oxymetazoline, norepinephrine, phenylpropanolamine, pseudoephedrine, naphazoline, xylometazoline, propylhexedrine, levodesoxyephedrine, ephedrine, adrenochrome, tetrahydrozoline, and mixtures thereof. 
     
     
         6 . The method of  claim 1 , wherein said vasoconstriction agent is selected from the group consisting of those vasoconstriction agents which exhibit vasoconstrictive effect for at least as long as phenylephrine exhibits vasoconstrictive effect after intranasal application, and mixtures thereof. 
     
     
         7 . The method of  claim 1 , wherein said vasoconstriction agent is oxymetazoline. 
     
     
         8 . The method of  claim 1 , wherein said composition is a paste. 
     
     
         9 . The method of  claim 1 , wherein said composition further comprises calcium alginate. 
     
     
         10 . The method of  claim 1 , said step of administering including administering topically and intranasally. 
     
     
         11 . The method of  claim 10 , wherein said step of administering includes providing said composition disposed on an applicator device and then applying said applicator device intranasally to said patient. 
     
     
         12 . The method of  claim 11 , wherein said applicator device is selected from the group consisting of applicators, pledgets, nasal tampons, and nasal packs. 
     
     
         13 . A composition for treating epistaxis in a human, said composition comprising bismuth subgallate and a vasoconstriction agent together in a ratio of 0.01-5 ml aqueous liquid containing vasoconstriction agent per 1 gram of bismuth subgallate powder, said composition being effective for treating epistaxis in a human when administered to a human patient suffering from epistaxis, said bismuth subgallate being present in said composition in a weight percent effective to assist in slowing or stopping epistaxis, said vasoconstriction agent being present in said composition in a weight percent effective to assist in slowing or stopping epistaxis, said weight percent of bismuth subgallate and said weight percent of said vasoconstriction agent being effective, in combination, to treat epistaxis when said composition is administered to a human patient suffering from epistaxis. 
     
     
         14 . The composition of  claim 13 , wherein said ratio is 0.1-3 ml aqueous liquid containing vasoconstriction agent per 1 gram of bismuth subgallate powder. 
     
     
         15 . The composition of  claim 13 , wherein said ratio is 0.3-2 ml aqueous liquid containing vasoconstriction agent per 1 pram of bismuth subgallate powder. 
     
     
         16 . The composition of  claim 13 , said vasoconstriction agent being selected from the group consisting of those vasoconstriction agents which exhibit vasoconstrictive effect for at least as long as phenylephrine exhibits vasoconstrictive effect after intranasal application, and mixtures thereof. 
     
     
         17 . The composition of  claim 13 , wherein said vasoconstriction agent is oxymetazoline. 
     
     
         18 . The composition of  claim 13 , wherein said composition is a paste. 
     
     
         19 . The composition of  claim 13 , wherein said composition further comprises calcium alginate. 
     
     
         20 . The composition of  claim 13 , further comprising an applicator device, said composition being disposed on said applicator device. 
     
     
         21 . The composition of  claim 13 , further comprising an applicator device, said composition being disposed on said applicator device, said applicator device being selected from the group consisting of applicators, pledgets, nasal tampons, and nasal packs. 
     
     
         22 . The composition according to  claim 13 , wherein said vasoconstriction agent is selected from the group consisting of epinephrine, phenylephrine, oxymetazoline, norepinephrine, phenylpropanolamine, pseudoephedrine, naphazoline, xylometazoline, propylhexedrine, levodesoxyephedrine, ephedrine, adrenochrome, tetrahydrozoline, and mixtures thereof. 
     
     
         23 . The composition according to  claim 13 , wherein said composition comprises a combination of bismuth subgallate and 0.05% oxymetazoline aqueous solution. 
     
     
         24 . The composition according to  claim 13 , wherein said composition comprises 0.1-3 ml of 0.05% oxymetazoline aqueous solution per 1 gram of bismuth subgallate powder. 
     
     
         25 . The composition according to  claim 13 , wherein said composition comprises 0.3-2 ml of 0.05% oxymetazoline aqueous solution per 1 gram of bismuth subgallate powder 
     
     
         26 . The composition according to  claim 13 , wherein said vasoconstriction agent is phenylephrine. 
     
     
         27 . The method according to  claim 1 , wherein said composition comprises a combination of bismuth subgallate and 0.05% oxymetazoline aqueous solution. 
     
     
         28 . The method according to  claim 1 , wherein said composition comprises 0.1-3 ml of 0.05% oxymetazoline aqueous solution per 1 gram of bismuth subgallate powder. 
     
     
         29 . The method according to  claim 1 , wherein said composition comprises 0.3-2 ml of 0.05% oxymetazoline aqueous solution per 1 gram of bismuth subgallate powder. 
     
     
         30 . The method according to  claim 1 , wherein said vasoconstriction agent is phenylephrine.